Literature DB >> 30416551

Direct Oral Anticoagulants: A Quick Guide.

Sikorska Julia1, Uprichard James1.   

Abstract

Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many years for patients with AF and other thrombotic conditions. The introduction of direct oral anticoagulants (DOACs) as alternatives represents a major advance in anticoagulation. DOACs have been found to be at least as safe and effective as vitamin K antagonists in randomised, controlled trials for stroke prevention in AF and the management of venous thromboembolism, with real-world data showing similar outcomes. With the availability of several agents, selecting the most appropriate DOAC can be challenging. The aim of the present article is to provide useful guidance on the implementation of DOAC treatment in clinical practice.

Entities:  

Keywords:  AF; direct oral anticoagulant; venous thromboembolic event; vitamin K antagonist

Year:  2017        PMID： 30416551      PMCID： PMC6206466          DOI： 10.15420/ecr.2017:11:2

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN： 1758-3756


  33 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply.

Authors:  G D Barnes; W Ageno; J Ansell; S Kaatz
Journal:  J Thromb Haemost       Date:  2015-09-30       Impact factor: 5.824

Review 3.  New oral anticoagulants and the cancer patient.

Authors:  Nicholas J Short; Jean M Connors
Journal:  Oncologist       Date:  2013-12-06

4.  Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.

Authors:  T van der Hulle; P L den Exter; J Kooiman; J J M van der Hoeven; M V Huisman; F A Klok
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

5.  Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta.

Authors:  Priya Bapat; Reuven Kedar; Angelika Lubetsky; Jeremy N Matlow; Katarina Aleksa; Howard Berger; Gideon Koren
Journal:  Obstet Gynecol       Date:  2014-06       Impact factor: 7.661

6.  New oral anticoagulants in patients with cancer: current state of evidence.

Authors:  Partha Sardar; Saurav Chatterjee; Eyal Herzog; Gerald Pekler; Savi Mushiyev; Luciano J Pastori; Ferdinand Visco; Wilbert S Aronow
Journal:  Am J Ther       Date:  2015 Nov-Dec       Impact factor: 2.688

7.  Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.

Authors:  Gianluigi Savarese; Robert P Giugliano; Giuseppe M C Rosano; John McMurray; Giulia Magnani; Gerasimos Filippatos; Santo Dellegrottaglie; Lars H Lund; Bruno Trimarco; Pasquale Perrone-Filardi
Journal:  JACC Heart Fail       Date:  2016-09-07       Impact factor: 12.035

Review 8.  Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.

Authors:  Robert J Romanelli; Laura Nolting; Marina Dolginsky; Eunice Kym; Kathleen B Orrico
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-01-26

9.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

10.  Development and Validation of an Oral Anticoagulation Knowledge Tool (AKT).

Authors:  Kehinde O Obamiro; Leanne Chalmers; Luke R E Bereznicki
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240
View more
  21 in total

1.  A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management.

Authors:  Charlotte S Yang; Rosaleen Boswell; Tammy J Bungard
Journal:  Eur J Clin Pharmacol       Date:  2021-01-06       Impact factor: 2.953

Review 2.  Potential Drug Interactions Between Cannabinoids and Its Derivatives and Oral Anticoagulants.

Authors:  McKenzie Paduch; Angela R Thomason
Journal:  Hosp Pharm       Date:  2021-01-09

3.  2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.

Authors:  Biykem Bozkurt; Sandeep R Das; Daniel Addison; Aakriti Gupta; Hani Jneid; Sadiya S Khan; George Augustine Koromia; Prathit A Kulkarni; Kathleen LaPoint; Eldrin F Lewis; Erin D Michos; Pamela N Peterson; Mohit K Turagam; Tracy Y Wang; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2022-06-23       Impact factor: 27.203

4.  Massive Left Ventricular Thrombus Causing Bilateral Posterior Cerebral Artery Stroke: A Case Report and Review of Literature.

Authors:  Ashali Jain; Asad Haider; Tyler S Jones
Journal:  Cureus       Date:  2022-08-01

Review 5.  2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards.

Authors:  Biykem Bozkurt; Sandeep R Das; Daniel Addison; Aakriti Gupta; Hani Jneid; Sadiya S Khan; George Augustine Koromia; Prathit A Kulkarni; Kathleen LaPoint; Eldrin F Lewis; Erin D Michos; Pamela N Peterson; Mohit K Turagam; Tracy Y Wang; Clyde W Yancy
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-06-23

6.  Emergency fasciotomy in an anticoagulated patient with low energy posterior thigh injury.

Authors:  Verity Brooker; Robert Brown; Luke Thornton; Edward Wood
Journal:  BMJ Case Rep       Date:  2020-09-07

7.  Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.

Authors:  Sarah A Nisly; Alexandra E Mihm; Chris Gillette; Kyle A Davis; Janine Tillett
Journal:  J Thromb Thrombolysis       Date:  2021-03-16       Impact factor: 2.300

8.  A Network Meta-Analysis Comparing Osteoporotic Fracture among Different Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation.

Authors:  Dibbendhu Khanra; Anindya Mukherjee; Saurabh Deshpande; Hassan Khan; Sanjeev Kathuria; Danesh Kella; Deepak Padmanabhan
Journal:  J Bone Metab       Date:  2021-05-31

Review 9.  Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Authors:  Robert Benamouzig; Maxime Guenoun; David Deutsch; Laurent Fauchier
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-18       Impact factor: 3.947

10.  Serum or Plasma for Quantification of Direct Oral Anticoagulants?

Authors:  Rachel Aakerøy; Charlotte L Stokes; Marija Tomić; Solfrid Hegstad; Ann Helen Kristoffersen; Hanne Ellekjær; Jan Schjøtt; Olav Spigset; Arne Helland
Journal:  Ther Drug Monit       Date:  2022-01-20       Impact factor: 3.118
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.